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Abstract
Fibrosis represents a major global disease burden, yet a potent antifibrotic compound is still not in
sight. Part of the explanation for this situation is the difficulties that both academic laboratories and
research and development departments in the pharmaceutical industry have been facing in re-
enacting the fibrotic process in vitro for screening procedures prior to animal testing. Effective in
vitro characterization of antifibrotic compounds has been hampered by cell culture settings that are
lacking crucial cofactors or are not holistic representations of the biosynthetic and depositional
pathway leading to the formation of an insoluble pericellular collagen matrix. In order to appreciate
the task which in vitro screening of antifibrotics is up against, we will first review the fibrotic process
by categorizing it into events that are upstream of collagen biosynthesis and the actual biosynthetic
and depositional cascade of collagen I. We point out oversights such as the omission of vitamin C,
a vital cofactor for the production of stable procollagen molecules, as well as the little known in
vitro tardy procollagen processing by collagen C-proteinase/BMP-1, another reason for minimal
collagen deposition in cell culture. We review current methods of cell culture and collagen
quantitation vis-à-vis the high content options and requirements for normalization against cell
number for meaningful data retrieval. Only when collagen has formed a fibrillar matrix that
becomes cross-linked, invested with ligands, and can be remodelled and resorbed, the complete
picture of fibrogenesis can be reflected in vitro. We show here how this can be achieved. A well
thought-out in vitro fibrogenesis system represents the missing link between brute force chemical
library screens and rational animal experimentation, thus providing both cost-effectiveness and
streamlined procedures towards the development of better antifibrotic drugs.
Fibrosis - ubiquitous problem and global burden
Repair of damaged tissues is an essential biological proc-
ess which allows directed replacement of dead or dam-
aged cells with connective tissue after injury. The repaired
area is addressed as a scar. Hence, scarring represents a
survival mechanism that is conserved throughout evolu-
tion and appears to be most pronounced in humans. If
this wound healing process goes awry, fibrosis results,
often causing an excessively large scar or the scarry trans-
formation of organ parts or whole organs. Besides local
scarring at sites of acute trauma, a variety of other causes,
such as chronic infections, chronic exposure to alcohol
and other toxins, autoimmune and allergic reactions,
radio- and chemotherapy, can all lead to fibrosis. This
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pathological process, therefore, can occur in almost any
organ or tissue of the body and, typically, results from sit-
uations persisting for several weeks or months in which
inflammation, tissue destruction and repair occur simul-
taneously. In this setting, fibrosis most frequently affects
the lungs, liver, skin and kidneys. There are approximately
5 million cases of idiopathic lung fibrosis globally [1], not
counting rare disorders like cystic fibrosis or very com-
mon ones such as asthma. Chronic hepatitis virus B and C
are a major cause of liver fibrosis/cirrhosis which currently
ranks 18th of the global disease burden [2]. Scar forma-
tion after myocardial infarction can on one hand prevent
the injured myocardium from dilatation and rupture but,
on the other hand, it can impair cardiac function through
increasing ventricular wall stiffness [3]. Atherosclerotic
lesions contain fibrotic tissue which can occupy up 87%
of total plaque area [4].
Peri-implantational fibrosis represents a current clinical
roadblock in regenerative medicine, which is gaining
attention in the tissue engineering field. Every implant is
surrounded by a fibrotic tissue reaction that depends on
the material, its surface and its degradation profile [5-7].
This is a consequence of chronic local inflammation and
a reflection of the host's tissue attempt to destroy the
implant or to cope with it. If destruction is not an option,
the implants get wrapped in a fibrous shroud with sparse
or no vascularization, so that it becomes effectively iso-
lated from the surrounding tissue. This is seen in artificial
ligaments [8,9], implanted biosensors [10,11], joint
implants [12,13], breast implants [14,15], encapsulated
tissues/cells [16,17], drug delivery systems [18] and eye
implants [19,20], and regularly impairs the proper func-
tion of the implant. This has prompted the field to alter
surface structures and coatings to contain this problem
[5,21-27]. A potential strategy could be to develop bioma-
terials that will deliver an antifibrotic substance locally
[15,28,29].
It becomes clear that the development of effective antifi-
brotics is an important unmet clinical need and with it
remains the necessity for rapid in vitro screening tools to
characterize lead antifibrotic compounds before they are
tested in animal models. This review will focus on the cur-
rent state of the art to emulate a fibrotic process in vitro,
the associated challenges and pitfalls and suggestions on
how to address them.
Fibrogenesis in vivo - complexity and key players
In order to appreciate the task which in vitro screening of
antifibrotics is up against, we shall dissect the fibrotic
process into two categories: first, events that are upstream
of collagen biosynthesis; and, secondly, the biosynthetic
and depositional cascade of collagen I.
Upstream events of fibrosis - cellular players in vivo
Trauma disrupts the anatomical cohesion of tissue struc-
tures, most evident by bleeding which indicates breakage
of blood vessels and disruption of their endothelial lin-
ing. This immediately induces a haemostatic response
encompassing platelet aggregation, blood clot formation
and accumulation of provisional ECM [30]. Damaged epi-
thelia secrete cytokines, growth factors and chemoattract-
ants for mononuclear cells to phagocytose cellular debris
at the site of injury and for fibroblasts to deposit collagen
and remodel it. Thus, a scar is formed that eventually
matures. The origin of these fibroblasts is currently a mat-
ter of debate. They are either differentiating homing mes-
enchymal stem cells [31], fibrocytes from the blood
circulation [32] or are derived from epithelia via epithe-
lial-mesenchymal transition (EMT) [33]. The fibroblasts
involved in scarring have a myofibroblast phenotype
characterised by α-smooth muscle actin (α-SMA) expres-
sion, increased secretion of collagen type I and III, and
contractility [30]. These cells are believed to be responsi-
ble for the majority of collagen production in most
organs.
'Soluble' factors mediating fibrosis
The cellular effectors of fibrosis are activated and pheno-
typically modulated by humoral players, namely chemok-
ines, growth factors and cytokines. Most notorious is
transforming growth factor β1 (TGF-β1) which supports
wound healing and repair. Under pathological condi-
tions, TGF-β1 coordinates a cross-talk between parenchy-
mal inflammatory and collagen-expressing cells, and
plays a key role in fibrosis progression. TGF-β1 is often
referred to as a 'soluble' factor. We use quotation marks
here because TGF-β1 is stored in its latent form bound to
TGF-β1 binding proteins in the matrix [34], and can in its
active form be scavenged and possibly neutralized by
decorin-mediated binding into the ECM [35,36] (for
review see [37]).
Along with factors such as the epithelial growth factor,
basic fibroblast growth factor and interleukin-1, TGF-β1
appears to play a key role in EMT [32]. The connective tis-
sue growth factor [38] and platelet-derived growth factor
[39] have also been reported to be involved in fibrosis (for
a more in-depth review on cytokines and molecular mech-
anisms involved in fibrogenesis, refer to [40]). Inflamma-
tion typically precedes fibrosis, although it has been
demonstrated that fibrosis is not always driven by inflam-
mation. This suggests that the mechanisms that regulate
fibrogenesis are, to a certain extent, distinct from those
regulating inflammation [41]. This may explain the lack
of efficacy of anti-inflammatory compounds in the treat-
ment of fibrotic disease [42]. Antifibrotic strategies at the
upstream level aim to interfere with fibrotic growth fac-
tors and make use of interfering antibodies [43-46], smallFibrogenesis & Tissue Repair 2009, 2:7 http://www.fibrogenesis.com/content/2/1/7
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molecules [39,47], proteins [48,49], antisense technology
[50,51] or the use of human recombinant TGF-β3. TGF-β3
is an alleged TGF-β1 antagonist that has shown some
promise in phase III clinical trials in a prophylactic setting
of small skin wounds [52].
Understanding the last mile of the fibrotic pathway
Irrespective of upstream events that trigger and entertain
fibrosis, the final product of cellular activity is the massive
deposition of collagen which results in scar formation,
organ or peri-implantational fibrosis. Therefore, we
would like to turn now to the obvious target in fibrosis,
namely the biosynthetic pathway of collagen itself.
The overall amount of collagen deposited by fibroblasts is
a regulated balance between collagen synthesis and colla-
gen catabolism, which is a carefully controlled process.
During a pathological maturation and remodelling phase,
collagen synthesized by fibroblasts exceeds the rate at
which it is degraded such that the net amount of collagen
continues to increase. There are several key points along
the collagen biosynthesis pathway that can be targeted to
effect a net reduction of collagen secretion and/or deposi-
tion (Figure 1). Transcription interference can be affected
using histone deacetylase inhibitors [53,54] or substances
like halofuginone [55,56]. At the post-transcriptional
level, siRNA targeting growth factors and key players have
been investigated [50,51,57] and, recently, we and others
have suggested the use of microRNAs [58,59]. Interfering
with post-translational modifications by inhibiting pro-
lyl-4 hydroxylase renders collagen triple helices less ther-
mostable and prevents their secretion [59,60], down-
regulation of collagen chaperone hsp47 does likewise
[61,62]. At the extracellular level, inhibition of procolla-
gen C-proteinase/BMP1 prevents the removal of the C-ter-
minal propeptide from the procollagen I molecule and,
thus, the supramolecular assembly of collagen into fibrils
[47,59]. Inhibition of lysyl oxidase mediation of inter-
molecular cross-links between collagen triple helices can
reduce collagen content of the ECM, presumably by ren-
dering collagen aggregates more susceptible to proteolytic
remodelling [63]. Similarly, the administration of hepato-
cyte growth factor [64] and matrix metalloproteinase 1
(MMP1) [48,49] increases collagen turnover in the ECM.
It becomes clear that a meaningful in vitro system for the
testing and characterization of antifibrotics should be able
to emulate the above described complete collagen matrix
formation cascade, encompassing its biosynthesis and all
post-translational (intra- and extra-cellular) modifica-
tions that give rise to a stable supramolecular assembly,
and also ideally allow the study of remodelling/fibrolysis.
For the sake of convenience and efficiency for screening
purposes, quantitation of collagen and other proteins of
interest should preferentially be in and from one well.
Fibrogenesis in vitro - constraints and options
The task of emulating collagen matrix formation in vitro
has been surprisingly difficult, partly due to the omission
of important cofactors and partially because of intrinsic
properties of contemporary cell culture conditions that
still are largely unknown. We will discuss these problems
and their solutions.
Biosynthetic issues - getting collagen made and deposited 
in vitro
(1) The first challenge for in vitro fibrogenesis is the suffi-
cient production of collagen and its subsequent incorpo-
ration into a pericellular matrix. The omission of ascorbic
acid in cell culture [38,65,66] results in minimal produc-
tion and deposition of collagen on the cell layer. Ascor-
bate is a crucial cosubstrate of the enzymes responsible for
the post-translational hydroxylation of prolyl and lysyl
residues necessary for rendering the collagen triple helix
thermostable, as well as for the extracellular cross-linking
of collagen fibers, respectively [67,68]. In other words,
scurvy can exist in cell culture. However, like its counter-
part in vivo, it can be easily treated in vitro by the adminis-
tration of ascorbate. On the other hand, L-ascorbic acid
has a short half-life in culture and completely oxidizes
after 3 days, so use of the stable form of ascorbate, such as
a magnesium salt of L-ascorbic acid 2-phosphate hexahy-
drate, is highly recommended [67].
About 23% of the collagen molecule is composed of pro-
line and hydroxyproline. As a non-essential amino acid,
proline is synthesized from arginine/ornithine via the
urea cycle and glutamate (directly or indirectly from
glutamine via glutaminase) through the citric acid cycle.
Clinical observations in burn patients suggest a drain of
arginine, ornithine and glutamate [69], while wound
fluid proline levels are at least 50% higher than plasma
levels, suggesting active import of proline into the wound
[70]. Providing additional proline or glutamine in the diet
to enhance collagen biosynthesis, however, does not
result in increased collagen accumulation. In contrast,
arginine, and ornithine supplementation are most effec-
tive in increasing collagen deposition [71]. As cell culture
media contains L-arginine and are usually supplemented
with L-glutamine, direct proline supplementation of cell
cultures in static and bioreactor conditions is not neces-
sary for increasing collagens synthesis, as also shown
recently [72]. However, systematic studies of proline-pre-
cursor supplementation in vitro under conditions of
increased synthesis and deposition have yet to be con-
ducted.
(2) Even under ascorbate supplementation, fibroblasts
deposit only minimal amounts of secreted collagen I into
their matrices. The reason for this lies in the tardy procol-
lagen C-proteinase/BMP1 activity under current aqueousFibrogenesis & Tissue Repair 2009, 2:7 http://www.fibrogenesis.com/content/2/1/7
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Potential points of interference along the collagen biosynthesis pathway Figure 1
Potential points of interference along the collagen biosynthesis pathway. (1) Epigenetic level: HDAC inhibitors. (2) 
Post-transcriptional level: mRNA translation is reduced by miRNAs/siRNAs. (3) Post-translational level: prolyl-4-hydroxylase 
inhibitors reduce the stability of the procollagen triple helix. (4) Reduction/inhibition of the collagen chaperone hsp47 (pink 
crescent symbol) also reduces stability of the procollagen triple helices, resulting in intracellular retention and degradation. (5) 
Post-secretional level: Inhibition of procollagen proteinases (scissors symbol) prevents deposition of insoluble collagen mole-
cules on the cell layer. (6) Collagen crosslinking: Inhibition of lysyl oxidase (LOX) hypothetically renders the collagen more sus-
ceptible to degradation. 7) An increase of MMP1 (orange Pacman symbol) results in faster collagen degradation and turnover.Fibrogenesis & Tissue Repair 2009, 2:7 http://www.fibrogenesis.com/content/2/1/7
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culture conditions. This results in an accumulation of
unprocessed procollagen in the cell culture medium [73]
where it does not belong and is discarded with every
medium change. Analytical methods have, therefore,
mostly focused on the convenient measurement of pro-
collagen secreted into culture medium. This may be suffi-
cient to assess compounds that primarily influence
biosynthesis and/or secretion, but it would not allow
assessment of any later step in collagen matrix formation.
To improve collagen deposition in cell culture, a fibropla-
sia model was developed using hyperconfluent human
dermal fibroblasts exposed to TGF-β1 for up to 1 month
to allow the formation of a fibroplastic tissue [63]. In an
abbreviated form (8 days TGF-β1 treatment) this model is
in use at Pfizer Global R&D (Sandwich, Kent). This model
moves closer to emulating the entire collagen biosynthesis
pathway as it allows the assessment of procollagen C-pro-
teinase inhibitors, which are predicted to interfere with
collagen deposition [47]. Destructive analysis of depos-
ited collagen by high-performance liquid chromatogra-
phy of 4-hydroxyproline is performed on the insoluble
culture fraction. Our laboratory has systematically devel-
oped technology to accelerate collagen deposition in vitro
by introducing macromolecules into the culture medium.
We have developed two deposition technologies that dif-
fer in terms of speed and morphology of the deposited
collagen. The first approach employs charged macromol-
ecules such as dextran sulphate 500 kDa (DxS) and polys-
odium-4-styrene sulfonate [61]. DxS leads to a granular
deposition of collagen within 48-72 h, exceeding that of
non-crowded cultures by 20- to 30-fold within the same
time frame. The second approach using neutral macro-
molecules in a Ficoll cocktail (Fc) [59] increases collagen
deposition 10-fold in 6 days and in a reticular deposition
pattern (Figure 2B). Both approaches are based on the cre-
ation of the excluded volume effect as explained else-
where [61,73,74]. Briefly macromolecules drive reaction
partners into closer collaboration resulting in improved
protein folding and protein-protein interactions. In the
case of fibrogenic cell culture, the conversion of procolla-
gen to collagen is sped up as well as the supramolecular
assembly of collagen triple helices to form fibres.
Quantitative issues - measuring collagen and normalizing 
the data
(3) Determination of the amount of collagen produced in
vitro is the next challenge, and this can be done in a variety
of ways ranging from simple colorimetric assays to elabo-
rate chromatographic procedures using radioactive and
non-radioactive material. What most of these procedures
have in common is the need to destroy the cell layer to
obtain solubilized collagen from the pericellular matrix.
The oldest established colorimetric method employs chlo-
ramine-T method to measure hydroxyproline [75]. The
destructive pre-solubilization requirement of collagen for
this assay, lack of specificity in discriminating between
collagen types, as well as a lack of internal normalization
within samples, are disadvantages in a screening setting.
The Sirius dye has been used since 1964 to identify colla-
gen in histology specimens [76,77]. It is based on the
selective binding of Sirius Red F3BA to collagen. Subse-
quent elution with sodium hydroxide-methanol and
read-out at 540 nm can be done in cuvettes, in microtiter-
plates with collagen extract adsorbed to the plastic and
using microplate readers [66,78,79]. Biocolor Ltd
(County Antrim, Northern Ireland, UK) made the Sircol™
Collagen Assay commercially available in 2007. Precipita-
tion of soluble collagen with the Sirius Red dye is required
prior to release of the dye with an alkali. In our hands, this
assay grossly overestimates collagen and procollagen
secreted into cell culture medium due to interference of
non-collagenous serum proteins, so we would recom-
mend prepurification (peptic digest and ultrafiltration) to
improve both sensitivity and specificity (Ricky R Lareu,
Dimitrios Zeugolis and Michael Raghunath, unpublished
experiments). An interesting solution appears to be the
adsorption of this dye onto collagen deposited on the cell
layer in culture [80]. This was recently suggested in a mod-
ified version for the testing of antifibrotic agents [66],
although this screening system did not use or recommend
the addition of ascorbic acid [66]. Various enzyme-linked
immunoassays can be used to quantify specific collagen
types such as coating collagen extracts onto multiwell
plates followed by detection using antibodies, sandwich
assays and competitive enzyme immunoassays. These
assays are very suitable for assessing soluble collagen from
culture media but would require extraction and dialysis
procedures to release insoluble collagen from pericellular
matrices. In this case, normalization for differences
between protein amounts or cell numbers in samples is
not possible. The determination of the hydroxyproline/
proline ratio via HPLC is based on total hydrolysis of pro-
tein samples, separation of hydroxyproline from proline
and back calculating the possible collagen content of the
sample [81]. While this method allows for the analysis of
any given biological material in experienced laboratories,
it is not amenable to a screening setting and would not
allow for normalisation or discrimination between differ-
ent collagen types, the same holds true for metabolically
labelled cell cultures with the attending issues of isotope
handling [82]. Similar issues arise with gas chromatogra-
phy/mass spectrometry requiring derivatization using tri-
fluoroacetylation and methanol esterification of 4-
hydroxyproline in collagen. Incorporation of the stable
isotope of oxygen, 18O2, into collagen is also possible with
this method and enables the examination of collagen syn-
thesis in vitro [83]. Polyacrylamide gel electrophoresis can
be very collagen specific using metabolic labelling of cell
cultures with radiolabelled amino acids glycine and pro-Fibrogenesis & Tissue Repair 2009, 2:7 http://www.fibrogenesis.com/content/2/1/7
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The Scar-in-the-Jar system combines enhanced collagen deposition with optical analysis for in situ quantitation Figure 2
The Scar-in-the-Jar system combines enhanced collagen deposition with optical analysis for in situ quantitation. 
(A) Cell layers were pepsin digested, resolved by sodium dodecyl sulphate - polyacrylamide and silver stained. In comparison 
with fibroplasia models (FP1: Ref [61], FP2: Ref [45]), macromolecular crowding increased matrix formation including stronger 
lysyl oxidase-mediated cross-linking in both deposition modes (rapid: dextran sulphate [DxS]; accelerated: Ficoll cocktail [Fc]), 
within a shorter time frame. Note: the presence of collagen V in FP and the accelerated deposition mode and its absence in the 
rapid deposition mode. Collagen V is usually absent from fibrotic tissue; hence, the extracellular matrix obtained in the rapid 
deposition mode will probably be more similar to a fibrotic matrix. (B) Cell layers were immunostained for collagen I and 
fibronectin. Cell nuclei were stained with 4', 6-diamidino-2-phenylindoldilactate (DAPI). The rapid deposition mode (negatively 
charged, DxS) produces granular collagen I and fibronectin within 2 days, and the accelerated mode (neutral, Fc) produces col-
lagen I with a reticular deposition pattern within 6 days. Therefore, the amount, velocity and morphology of deposited collagen 
can be manipulated depending on the macromolecules used. (C) Optical analysis of deposited collagen I using a 2× objective, 
eliminated corner auto-fluorescence in the four corner fields with triangular masks to conceal these regions during quantita-
tion. (D) Cytometry and quantitation of the area of deposited collagen I in a 24-well multiplate format enabled identification of 
antifibrotic substances that perturb the collagen biosynthesis pathway resulting in a net reduction of deposited collagen I. (i) 
DAPI-stained nuclei at 20× total magnification in monochrome pseudocolour, 600× magnification (inset). (ii) Red scored nuclei 
by Count Nuclei module for cytometry. (iii) Immunostained deposited collagen I. (iv) Regions with fluorescent pixel intensity 
above a selected value based on controls are demarcated by the software in green for quantitation of deposited collagen I area 
at 100× magnification. This figure is reproduced with permission (Ref [59]).Fibrogenesis & Tissue Repair 2009, 2:7 http://www.fibrogenesis.com/content/2/1/7
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line [84] and subsequent detection of radioactive bands
using fluorography [85]. Metabolic labelling can be
replaced with safer and very sensitive silver staining or
immunoblotting [61]. The latter has the advantage of dif-
ferentiating between various collagen types and compari-
son with an internal standard like actin as a cell mass
equivalent for normalization. Collagen antibodies tend to
recognize protein conformation in addition to sequence
specificity, which can pose a problem for the detection of
denatured collagen α-chains in sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE), hence
native PAGE might be an alternative option [86]. All gel
electrophoresis-based approaches are excellent qualitative
and quantitative back-up techniques. However, their
laboriousness would exclude them as screening tools.
(4) Normalization of data to account for cell number var-
iations is another important consideration. Most of the
methods discussed above lack the option of normaliza-
tion and the use of parallel cultures subjected to the sepa-
rate measurement of total protein or DNA content. In any
case, cell density influences the amount of collagen
deposited: in fact, subconfluent cultures produce the most
collagen [87]. Depending on the substance screened, inhi-
bition or stimulation of proliferation, or cytotoxicity may
occur. As this certainly will impact on the collagen
amount secreted/deposited, well-to-well variances not
withstanding, the acquired data must account for these
changes in cell number/density. Data normalization
methods involve the destruction of cell layers to quantify
housekeeping proteins by Western blot or DNA [81,83].
This not only increases sample-processing steps, but also
cumulates error.
Qualitative issues - looking beyond collagen I
(5) Fibrosis is not only characterized by an excess build-
up of collagen I but, depending on the tissue context,
other proteins might be of interest. Also, the transition of
fibrogenic cells from a quiescent fibroblast stage to a
fibrotic myofibroblast phenotype should be considered.
Markers such as α-SMA or fibroblast activation protein-α
[88] are up-regulated in stimulated fibroblasts and a sur-
vey of the production and deposition of non-collagenous
extracellular matrix (ECM) proteins as an internal control
for the action of antifibrotic agents would be desirable. As
well as capturing the actual number of cells in a given
well, options for a high content read-out covering as many
of the above markers as possible in addition to collagen I
would constitute an ideal antifibrotic screening system.
A current solution: the Scar-in-a-Jar
The Scar-in-a-Jar has been developed in our laboratory in
order to address the problems of in vitro fibrogenesis dis-
cussed above. This system: (1) solves the problem of tardy
collagen deposition; (2) quantitatively measures relative
changes in collagen I deposition via immunofluorescence
and in situ optical analysis; (3) allows for high content
screening within a single well including α-SMA and
another ECM protein of choice; and (4) while implement-
ing normalization for cell number by counting nuclei via
4',6-diamidino-2-phenylindoldilactate (DAPI) staining
[59]. As discussed above, the addition of charged and neu-
tral macromolecules into culture medium dramatically
enhances the deposition of collagen into the pericellular
matrix [61] (Figure 2B), within a shorter time, to a greater
extent and degree of cross-linking than possible in both
fibroplasia models by Clark et al. (1997) [63] and Fish et
al. (2007) [47] (Figure 2A). In both cases, enhanced colla-
gen deposition reduces culture time to 48 h (DxS) and 6
days (Fc), prior to optical quantitation. TGF-β1 addition
is optional. For optical analysis, samples in a 24-well for-
mat are immunostained for collagen I and fibronectin,
and cell nuclei are stained with DAPI. Automated image
acquisition using a 2× objective is performed and the area
of collagen I and fibronectin per cell is ascertained using
the Metamorph® Imaging System software (Figure 2C-D).
The Scar-in-a-Jar enables the analysis of proteins-of-inter-
est and cell enumeration all within a single-well, thus
minimizing processing steps, material loss and sample
variation. Cell enumeration can give an indication of
potential anti-proliferative effects of a compound and
allows for correction of protein production to account for
the variance in cell numbers due to that compound. We
also demonstrated its capability to discern the reduction
of deposited collagen by known and novel inhibitors tar-
geting various points of the collagen biosynthesis path-
way from the epigenetic to the extracellular level,
including two C-proteinase inhibitors, FSY002, originally
developed in a German pharmaceutical company [89]
and PCP56 from Pfizer (NY, USA) [47]. PCP56 demon-
strated efficacy in agreement with an earlier report on the
abridged fibroplasia model [47] but FSY002 did not work
in our system. FSY002 has an interesting history. This
phosphinate inhibitor did inhibit purified C-proteinase in
the test tube and an IC50 value could be obtained [89].
However, tests in conventional monolayer fibroblast cul-
ture proved inconclusive and we have to conclude in
hindsight that this was due to tardy C-proteinase activity.
Running this substance in our system with fully active C-
proteinase activity revealed its ineffectiveness. At this
point in time, optical analysis is unable to discern a reduc-
tion in collagen cross-links if there is no net collagen
reduction on the cell layer [59]. Hence, the testing of lysyl
oxidase inhibitors will be better analysed by the biochem-
ical analysis method employing pepsin digestion of cell
layers followed by SDS-PAGE and silver staining to visual-
ize collagen cross-links (Figure 2A) [85].Fibrogenesis & Tissue Repair 2009, 2:7 http://www.fibrogenesis.com/content/2/1/7
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The combination of short culture time, rapid collagen bio-
synthesis, complete deposition, together with optical
analysis that circumvents the need for protein extraction,
makes the Scar-in-a-Jar a convenient assay that remains in
a single well from start to finish.
Future developments
Besides the current use of fibroblasts, this system has the
flexibility and potential to screen the effect of potential
antifibrotic compounds on other organ specific culprits
such as hepatic stellate cells. The optical accessibility of
the Scar-in-a-Jar has room for the introduction of one or
more additional cell types like monocytes or smooth mus-
cle cells to augment the fibrotic context and tailor it for a
dermal wound healing situation or an atherosclerotic
plaque. This could be done in direct coculture or using
inserts, with the fibrotic target cells adhering to the bot-
tom of the well. Besides preliminary testing of exoge-
nously added matrix metalloproteinases [59], the current
system has not yet been fathomed for its ability to study
collagen matrix metalloproteinases turnover that would
be relevant for analysing effects of collagen cross-link
inhibitors and inducers of matrix metalloprtoteinases like
hepatocyte growth factor. We envision longer observation
times in this instance or challenging cell cultures after an
initial ECM build-up, with additional cell types or sub-
stances that induce remodelling. A very promising line of
research using this system could be non-enzymatic glyca-
tion studies to capture a diabetic situation and testing
breakers of advanced glycation end products.
Conclusions
With the current burden of fibrosis worldwide and
acquired connective tissue disorders as seen in diabetes,
the development of in vitro test systems that mimic fibro-
sis and connective tissue formation is more needed than
ever. The lack of adequate systems to study fibrogenesis in
vitro has either impeded the development of antifibrotics
or has forced research and development to move too early
into animal models. Although in vivo evaluation is pivotal
for preclinical development, a rapid in vitro quantitative
screening method is mandatory for the first round deter-
mination of potential anti-fibrotic compounds, since any
animal model represents the same complexity as a human
and unclear in vitro data will unlikely be cleared in vivo.
As there are several key points along the collagen biosyn-
thesis pathway that can be interfered with, it is necessary
to emulate all of these steps in vitro and, ideally, to get
high content information out of a single well. This prob-
lem has been finally solved with the Scar-in-a-Jar. How-
ever, we look forward with great interest to seeing
refinements and further developments of antifibrotics
screening in the quest for the most potent and versatile
antifibrotic compound.
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